Finan et al. (55) found that the hybrid thyroid hormone-glucagon 147 complex can improve the degree of liver steatosis in NAFLD patients without adverse reactions in the skeletal muscle and cardiovascular system. The gene discussed is GCG; the disease is fatty liver disease.